Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Prospective, open-label, two-way crossover, phase Ib drug-drug interaction study in patients
with advanced solid tumors.
The study consisting of two lurbinectedin cycles, one cycle in combination with bosentan and
one cycle as single agent (in different order depending on the study sequence), and one
additional third cycle of lurbinectedin as a single agent for patients who meet the
continuation criteria and obtain a clinical benefit after the first two cycles.